Physician profile
Jenna E Brown
NPI 1104292853
$2,247.43
in general payments reported to CMS, 2019-2025
25 companies · $590 in 2025
The $590 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.86 · 2022: $514 · 2023: $564 · 2024: $556 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $404.09 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $285.02 | 2022-2025 | |
| Amgen INC. | $204.21 | 2022-2024 | Otezla, Repatha, Prolia |
| Exact Sciences Corporation | $159.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $120.72 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $120.27 | 2023-2025 | Farxiga, Breztri |
| Abbvie INC. | $99.36 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $96.79 | 2023-2024 | Gemtesa |
| Lilly USA, LLC | $94.16 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $90.88 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Esperion Therapeutics, INC. | $85.21 | 2022-2023 | Nexletol |
| Novo Nordisk INC | $85.00 | 2022-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $71.60 | 2022 | |
| Pfizer INC. | $67.47 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $38.66 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $34.26 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $28.43 | 2022 | |
| Sanofi Pasteur INC. | $27.73 | 2022-2023 | |
| Daiichi Sankyo INC. | $27.25 | 2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $25.37 | 2024 | Givlaari |
| Allergan, INC. | $22.86 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.46 | 2023 | Livalo |
| Idorsia Pharmaceuticals US INC | $14.78 | 2023 | Quviviq |
| Opko Pharmaceuticals, LLC | $13.91 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.